NCT05134779 De-convoluting Interactions Between Genes, the Cancer Environment, and the Immune System to Develop Therapies That Work for You
| NCT ID | NCT05134779 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Weill Medical College of Cornell University |
| Condition | Breast Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 400 participants |
| Start Date | 2022-01-12 |
| Primary Completion | 2027-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 400 participants in total. It began in 2022-01-12 with a primary completion date of 2027-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a live biobank study for breast cancer (BC) patients where samples will be collected at inflection points in the course of the disease.
Eligibility Criteria
Inclusion Criteria: * All patients will historically proven BC are eligible to be on the study Exclusion Criteria: * Carriers of other cancers other than breast.
Contact & Investigator
Silvia Formenti, M.D.
PRINCIPAL INVESTIGATOR
Weill Medical College of Cornell University
Frequently Asked Questions
Who can join the NCT05134779 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 90 Years, studying Breast Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05134779 currently recruiting?
Yes, NCT05134779 is actively recruiting participants. Contact the research team at fgr4002@med.cornell.edu for enrollment information.
Where is the NCT05134779 trial being conducted?
This trial is being conducted at New York, United States, New York, United States.
Who is sponsoring the NCT05134779 clinical trial?
NCT05134779 is sponsored by Weill Medical College of Cornell University. The principal investigator is Silvia Formenti, M.D. at Weill Medical College of Cornell University. The trial plans to enroll 400 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.